CN1415603A - Salt of leonurine and its preparation - Google Patents
Salt of leonurine and its preparation Download PDFInfo
- Publication number
- CN1415603A CN1415603A CN 02138220 CN02138220A CN1415603A CN 1415603 A CN1415603 A CN 1415603A CN 02138220 CN02138220 CN 02138220 CN 02138220 A CN02138220 A CN 02138220A CN 1415603 A CN1415603 A CN 1415603A
- Authority
- CN
- China
- Prior art keywords
- salt
- acid
- leonurine
- delta
- processed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A leonurin salt is soluble salt which is prepared by reaction of leonurin on the acidic salt of inorganic, organic, or polybasic acid. It can be used to prepare tablet, capsule, softgel, particle, oral liquid, injection, syrup, etc.
Description
One, technical field
The present invention relates to a kind of alkaloid and preparation thereof, specifically a kind of syringic acid.delta.-guanidinobutyl ester inorganic salt and organic salt and preparation thereof.
Two, background technology
Motherwort Herb is the dry aerial parts of labiate Motherwort Herb Leonurns heterophyllus Sweet, is the herbal species that Chinese Pharmacopoeia records, and is gynaecology's Chinese medicine commonly used clinically, and effects such as the stasis of blood have menstruation regulating, invigorate blood circulation and dispel.Its effective ingredient is an alkaloid, and alkaloid mainly contains syringic acid.delta.-guanidinobutyl ester (C
14H
21O
5N
3) and stachydrine, studies show that syringic acid.delta.-guanidinobutyl ester has excitation to the uterus, be the major ingredient of Motherwort Herb performance curative effect, its effect is identical with motherwort formulation.Water insoluble from the syringic acid.delta.-guanidinobutyl ester that plant species extracts with synthetic, it is prepared into soluble salt, can conveniently make useful clinically preparation, do not see the report that syringic acid.delta.-guanidinobutyl ester is made soluble salt at present.
Three, summary of the invention
Problem to be solved by this invention is with syringic acid.delta.-guanidinobutyl ester and the reaction of the acid salt of the multiple mineral acid that medically allow to use or organic acid or polyprotonic acid makes soluble salt, is processed into relevant preparation again, and its good water solubility is beneficial to absorption of human body performance curative effect.
Syringic acid.delta.-guanidinobutyl ester is the alkaloid that contains guanidine radicals.The syringic acid.delta.-guanidinobutyl ester of monovalent can generate soluble salt with the acid-respons of monovalent, and said here acid is remaining carboxyl or acidic-group in monoprotic acid, polyprotonic acid or the polyprotonic acid acid salt.For example: a mole hydrochloride and sulfuric acid can be respectively generate corresponding salt with syringic acid.delta.-guanidinobutyl ester and two moles of syringic acid.delta.-guanidinobutyl esters reactions of one mole; Citric Acid contains three carboxyls, and one mole Citric Acid can generate corresponding salt with three moles syringic acid.delta.-guanidinobutyl ester reaction.And if Citric Acid acid salt reaction, one mole Citric Acid sodium dihydrogen can generate corresponding salt with two moles syringic acid.delta.-guanidinobutyl ester reaction, one mole Citric Acid one hydrogen sodium can generate corresponding salt with the reaction of one mole syringic acid.delta.-guanidinobutyl ester, other various acid can and the like.Here said acid is meant various mineral acids or the organic acid that medically allows, mineral acid is as hydrochloric acid, sulfuric acid, sulfurous acid, phosphoric acid, nitric acid etc., and organic acid is as: the straight chain of acetic acid, lactic acid, methylsulfonic acid, lactobionic acid, succsinic acid, Citric Acid, oxalic acid, fumaric acid, toxilic acid, L-glutamic acid, tartrate, aspartic acid, C1～12 and or branched chain fatty acid etc.The acid that is used to react can be above-mentioned mineral acid or the one or more kinds of mixing acid of organic acid, can be acid sodium salt (hydrogen sodium salt), acid sylvite (hydrogen sylvite) etc. if use the acid salt (hydrogen salt) of the above polyprotonic acid of binary.
Studies show that: preferable mineral acid has, hydrochloric acid, sulfuric acid, sodium pyrosulfate, sulfurous acid, sodium bisulfite, nitric acid, phosphoric acid, preferable organic acid has, acetic acid, lactic acid, methylsulfonic acid, lactobionic acid, succsinic acid, Citric Acid, oxalic acid, toxilic acid, L-glutamic acid, aspartic acid etc.
Behind syringic acid.delta.-guanidinobutyl ester and the various sour salify, detect through high performance liquid chromatography, the retention time and the syringic acid.delta.-guanidinobutyl ester of the aqueous solution of various leonurine salts are as broad as long, show that syringic acid.delta.-guanidinobutyl ester its structure behind salify does not change, in the aqueous solution, syringic acid.delta.-guanidinobutyl ester can be discharged, the effect identical can be brought into play in vivo with syringic acid.delta.-guanidinobutyl ester.
Its pH value of various water-soluble salts of the present invention preparation is in 4.0～7.0 scopes, and it is little to blood vessel irritation to be processed into injection, stability that also can fine assurance syringic acid.delta.-guanidinobutyl ester.
Syringic acid.delta.-guanidinobutyl ester inorganic salt or the organic salt preparation of containing of the present invention, comprise the various formulations that can take, as: tablet, granule, dispersible tablet, slow releasing tablet, controlled release tablet, capsule, soft capsule, dripping pill, oral liquid, syrup etc., the formulation of injectable administration, as: injection liquid, transfusion, powder pin etc.
The oral preparations of syringic acid.delta.-guanidinobutyl ester inorganic salt and organic salt can add suitable thinner, tackiness agent, disintegrating agent, lubricant, glidant and or suitable correctives.Injection can add water for injection dissolving, through gac remove thermal source, Sterile Filtration (millipore filtration of 0.22 μ m), aseptic subpackaged (embedding) with and the various injection types that form through suitable processes of the isoosmotic aqueous solution.
This preparation drug effect and toxicological test result:
Effect to the uterus: this product all is excitation to tame rabbit uterus, uterus to unpregnancy, early pregnancy, late pregnancy or postpartum is all effective, be the dose-dependently relation in the dosage range that acts on 0.1～0.2mcg/ml of leonurine salt (calculating) to the uterus by syringic acid.delta.-guanidinobutyl ester, dosage reaches maximum effect when surpassing 0.2mcg/ml, is lasting excitation.
Acute toxicity effect: irritate the LD that stomach gives mouse leonurine salt (calculating according to syringic acid.delta.-guanidinobutyl ester)
50Be 2452.8 ± 135.2mg/kg; Vein gives the LD of mouse leonurine salt (calculating according to syringic acid.delta.-guanidinobutyl ester)
50Be 601.2 ± 45.1mg/kg.
Four, embodiment () is an example with syringic acid.delta.-guanidinobutyl ester vitriol and acetate, and non-limiting examples is described below: 1. syringic acid.delta.-guanidinobutyl ester vitriol
Get syringic acid.delta.-guanidinobutyl ester elaboration 10g, add water 50ml, under the stirring at room state, the sulphuric acid soln that slowly adds 0.5N, all dissolve up to syringic acid.delta.-guanidinobutyl ester, the control reacting solution pH value is in 4.5～6.5 scopes, and the gac that adds 0.1g stirred 30 minutes, filter, get filtrate, concentrating under reduced pressure is placed, the crystallization that the filter collection is separated out gets the Motherwort Herb alkali sulfate.228～230 ℃ of fusing points.
This product is through high performance liquid chromatograph (chromatographic instrument: Shimadzu LC-10AT, detector: Shimadzu SPD-10AVP, chromatographic column: VP-ODS 150L * 4.6, measure wavelength: 254nm, moving phase: 0.025mol/L phosphoric acid solution (pH:3.5): acetonitrile=85: 15, flow velocity: 1.0ml/min, sample size: assay determination 20 μ g/ml), purity are 99.6%.
The crystallization experiment of syringic acid.delta.-guanidinobutyl ester vitriol:
Get syringic acid.delta.-guanidinobutyl ester vitriol 5g, add water 50ml dissolving, it is an amount of slowly to add 5% sodium hydroxide solution, to white occurring, the sodium hydroxide solution that continues Dropwise 5 % is separated out white precipitate fully, filter, wash with water, 80 ℃ of dryings 3 hours, get the white solid thing, this white solid thing is carried out infrared absorption spectrometry, and the gained data are compared with syringic acid.delta.-guanidinobutyl ester, and both are in full accord as a result.
Above experimental result shows that syringic acid.delta.-guanidinobutyl ester vitriol easily is decomposed into syringic acid.delta.-guanidinobutyl ester and sulfate radical in water, do not influence its stability behind syringic acid.delta.-guanidinobutyl ester and the sulfuric acid salify.2. the acetate of syringic acid.delta.-guanidinobutyl ester
Get syringic acid.delta.-guanidinobutyl ester elaboration 10g, add water 50ml, under the stirring at room state, the acetum that slowly adds 1.0N, all dissolve up to syringic acid.delta.-guanidinobutyl ester, the control reacting solution pH value is in 4.5～6.5 scopes, and the gac that adds 0.1g stirred 30 minutes, filter, get filtrate, concentrating under reduced pressure is placed, the crystallization that the filter collection is separated out gets the Motherwort Herb alkali sulfate.222～224 ℃ of fusing points.
This product is through high performance liquid chromatograph (chromatographic instrument: Shimadzu LC-10AT, detector: Shimadzu SPD-10AVP, chromatographic column: VP-ODS 150L * 4.6, measure wavelength: 254nm, moving phase: 0.025mol/L phosphoric acid solution (pH:3.5): acetonitrile=85: 15, flow velocity: 1.0ml/min, sample size: assay determination 20 μ g/ml), purity are 99.7%.
The crystallization experiment of syringic acid.delta.-guanidinobutyl ester acetate:
Get syringic acid.delta.-guanidinobutyl ester acetate 5g, add water 50ml dissolving, it is an amount of slowly to add 5% sodium hydroxide solution, to white occurring, the sodium hydroxide solution that continues Dropwise 5 % is separated out white precipitate fully, filter, wash with water, 80 ℃ of dryings 3 hours, get the white solid thing, this white solid thing is carried out infrared absorption spectrometry, and the gained data are compared with syringic acid.delta.-guanidinobutyl ester, and both are in full accord as a result.
Above experimental result shows that syringic acid.delta.-guanidinobutyl ester acetate easily is decomposed into syringic acid.delta.-guanidinobutyl ester and acetate in water, do not influence its stability behind syringic acid.delta.-guanidinobutyl ester and the acetic acid salify.(2), example of formulations 1. tablets
1.25,2.5,5,10,20,50,100, the 200mg/ sheet specification is (with the syringic acid.delta.-guanidinobutyl ester cubage):, below be to be the preparation process that example is set forth syringic acid.delta.-guanidinobutyl ester vitriol with specification 10mg/ sheet.Each supplementary material proportioning: with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Amylum pregelatinisatum 50g
Sodium starch glycolate 40g
Magnesium Stearate 5g
70% ethanolic soln is an amount of
Make 1000
Take by weighing syringic acid.delta.-guanidinobutyl ester vitriol, amylum pregelatinisatum, sodium starch glycolate by prescription, pulverize, cross 80 mesh sieves respectively, mix, do wetting agent system softwood with 70% ethanol, 18 mesh sieves are granulated, 60 ℃ of dryings 3～4 hours, the whole grain of 16 mesh sieves, add Magnesium Stearate, mixing, compressing tablet gets final product.
Getting dissolution rate (45 minutes) greater than 75% with water during for dissolution medium.2. (specification: each supplementary material proportioning same tablet): with the 10mg/ sheet is example to capsule
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Amylum pregelatinisatum 80g
Sodium starch glycolate 20g
70% ethanolic soln is an amount of
Make 1000
Take by weighing syringic acid.delta.-guanidinobutyl ester vitriol, amylum pregelatinisatum, sodium starch glycolate by recipe quantity, pulverize, cross 80 mesh sieves respectively, mix, with 7% ethanolic soln as wetting agent system softwood, cross 24 mesh sieves and granulate, 60 ℃ of dryings 3～4 hours, the whole grain of 20 orders, add Magnesium Stearate, mix, adjust loading amount according to content, in the capsulae vacuus of packing into promptly.
Getting dissolution rate (45 minutes) greater than 75% with water during for dissolution medium.3. each supplementary material proportioning of granule (the same tablet of dosage): with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Cane sugar powder 540g
Sodium starch glycolate 100g
Micro-crystalline cellulose 100g
Citric acid 50g
3%PVP solution is an amount of
Flavoring orange essence is an amount of
Make 1000 bags
Take by weighing syringic acid.delta.-guanidinobutyl ester vitriol, cane sugar powder, sodium starch glycolate, Microcrystalline Cellulose, citric acid according to recipe quantity, pulverize, cross 80 sieves, mix, make softwood with 3%PVP solution as wetting agent, cross 20 mesh sieves and granulate, 60 ℃ of dryings 3～4 hours, the whole grain of 18 orders, packing, promptly.4. each supplementary material proportioning of dispersible tablet: with the 10mg/ sheet is example:
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Microcrystalline Cellulose 80g
Low substituted cellulose 20g
Sodium starch glycolate 20g
Amylum pregelatinisatum 5g
Magnesium Stearate 5g
3%PVP (70% alcoholic solution) is an amount of
Make 1000
Take by weighing syringic acid.delta.-guanidinobutyl ester vitriol, Microcrystalline Cellulose, low substituted cellulose, sodium starch glycolate, amylum pregelatinisatum by prescription, pulverize, cross 80 mesh sieves respectively, mix, make wetting agent system softwood with 3%PVP solution, 18 mesh sieves are granulated, 60 ℃ of dryings 3～4 hours, the whole grain of 16 mesh sieves, add Magnesium Stearate, mixing, compressing tablet gets final product.
This product is disintegration in 3 minutes, with water be the dissolution rate (3 minutes) of medium greater than 75%, dispersing uniformity meets the relevant regulations of Chinese Pharmacopoeia version in 2000 after the sample dispersion.5. slow releasing tablet
10,30,60,90,120, the 150mg/ sheet dosage:
Each supplementary material proportioning: with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Xylo-Mucine 7.5g
Vltra tears 15g
Magnesium Stearate 0.5g
Make 1000 altogether
Get syringic acid.delta.-guanidinobutyl ester vitriol, Vltra tears, Xylo-Mucine respectively, pulverize, cross 60 mesh sieves.Take by weighing by recipe quantity respectively, principle according to " equivalent is progressively increased ", the powder mixes of auxiliary materials such as syringic acid.delta.-guanidinobutyl ester vitriol and Vltra tears, Xylo-Mucine is even, the water that adds recipe quantity, stir, add suitable quantity of water system softwood in case of necessity, granulate with 14 mesh sieves, in 55～60 ℃ of air seasonings, controlling moisture content＜3%, behind the whole grain of 12 mesh sieves, the Magnesium Stearate that adds recipe quantity, mixing, the hardness of control tablet is between 5.5～6.5kg, adjustment sheet is heavy, makes every to contain the main ingredient amount in about 100% of labelled amount.
Release characteristic: should should be more than 15%～45%, 40%～75% and 75% of labelled amount respectively mutually with 8 hours burst size in 1 hour, 4 hours.6. oral liquid (the same tablet of dosage)
Each supplementary material proportioning: with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Sucrose 100g
Citric acid 20g
Essence is an amount of
Distilled water adds to 5000ml
Make 1000
It is an amount of to get distilled water, and the supplementary material of recipe quantity is added stirring and dissolving in the entry, filters, and the subsequent filtrate adding distil water adds essence to 5000ml, stir, and packing, every 5ml, gland, 100 ℃ of sterilizations 1 hour, passed examination is promptly.7. each supplementary material proportioning of syrup (same tablet): with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Sucrose 600g
Citric acid 10g
Essence is an amount of
Distilled water adds to 5000ml
Make 1000
It is an amount of to get distilled water, and the supplementary material of recipe quantity is added stirring and dissolving in the entry, filters, and the subsequent filtrate adding distil water adds essence to 5000ml, stir, and packing, every 5ml, gland, 100 ℃ of sterilizations 1 hour, passed examination is promptly.8. be to be example explanation preparation method below the injection liquid (1.25,2.5,5,10,20,50,100,200mg/ prop up) with specification 10mg.Each supplementary material proportioning: with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Water for injection adds to 5000ml
Make 1000
Recipe quantity is got the Motherwort Herb alkali sulfate be dissolved in the water for injection, add 0.3% needle-use activated carbon, stirred 30 minutes, decarburization, Sterile Filtration (0.22 μ m millipore filtration), packing under aseptic condition, sealing by fusing, every 5ml sterilized 1 hour for 100 ℃, checked, promptly.The transfusion (the same injection liquid of specification) each supplementary material proportioning: with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
Sodium-chlor 850g
Water for injection adds to 100000ml
Make 1000 bottles
With recipe quantity get the Motherwort Herb alkali sulfate, sodium-chlor is dissolved in the water for injection, adds 0.3% needle-use activated carbon, stirs decarburization 30 minutes, Sterile Filtration (0.22 μ m millipore filtration), packing under aseptic condition, every bottle of 100ml, sterilized 1 hour for 100 ℃, check, promptly.10. each supplementary material proportioning of freeze-dried powder (the same injection liquid of specification): with the 10mg/ sheet is example
Syringic acid.delta.-guanidinobutyl ester vitriol (pressing syringic acid.delta.-guanidinobutyl ester calculates) 10g
N.F,USP MANNITOL 90g
Freeze-drying is made 1000
Get the syringic acid.delta.-guanidinobutyl ester vitriol and the N.F,USP MANNITOL of recipe quantity, add injection water and dissolve in right amount, control pH value adds the injection water to 1000ml between 4.0～6.5, mixing, add 0.3% needle-use activated carbon and stirred decarburization, Sterile Filtration (0.22 μ m millipore filtration) 30 minutes, packing under sterile state, every 1ml, lyophilize becomes white bulk or powder, promptly.
Claims (11)
1. leonurine salt, by a kind of salt that the acid salt prepared in reaction of syringic acid.delta.-guanidinobutyl ester and mineral acid or organic acid or polyprotonic acid obtains, it is characterized in that: described leonurine salt pH is 4～7.
2. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the tablet that leonurine salt is processed into auxiliary material.
3. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the capsule that leonurine salt is processed into auxiliary material.
4. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the granule that leonurine salt is processed into auxiliary material.
5. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the dispersible tablet that leonurine salt is processed into auxiliary material.
6. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the slow releasing tablet that leonurine salt is processed into auxiliary material.
7. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the oral liquid that leonurine salt is processed into auxiliary material.
8. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the syrup that leonurine salt is processed into auxiliary material.
9. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the injection liquid that leonurine salt is processed into auxiliary material.
10. the preparation that is processed into by the described leonurine salt of claim 1 is characterized in that: the transfusion that leonurine salt is processed into auxiliary material.
11. the preparation by the described leonurine salt of claim 1 is processed into is characterized in that: the freeze-dried powder that leonurine salt is processed into auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02138220 CN1415603A (en) | 2002-09-02 | 2002-09-02 | Salt of leonurine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02138220 CN1415603A (en) | 2002-09-02 | 2002-09-02 | Salt of leonurine and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1415603A true CN1415603A (en) | 2003-05-07 |
Family
ID=4749358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02138220 Pending CN1415603A (en) | 2002-09-02 | 2002-09-02 | Salt of leonurine and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1415603A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015561A1 (en) * | 2007-08-02 | 2009-02-05 | Fudan University | The use of leonurine and compositions thereof |
| CN103575816A (en) * | 2012-07-30 | 2014-02-12 | 天士力制药集团股份有限公司 | Method for detecting leonurine hydrochloride content in nephritis elimination tablet |
| CN108129355A (en) * | 2018-01-18 | 2018-06-08 | 旌德新星生物科技有限公司 | A kind of hydrochloric acid leonurine alpha-crystal form and its preparation method and application |
| WO2019080671A1 (en) * | 2017-10-23 | 2019-05-02 | 珠海横琴新区中珠正泰医疗管理有限公司 | Leonurine crystal and use thereof in preparation of insulin sensitizer, hypoglycemic drug and lipid-lowering drug |
| CN110123664A (en) * | 2019-05-22 | 2019-08-16 | 中科萱嘉医养(珠海)健康科技有限公司 | A kind of supermolecule composition containing leonurine or inclusion compound and the preparation method and application thereof |
| CN110251501A (en) * | 2019-06-14 | 2019-09-20 | 中科萱嘉医养(珠海)健康科技有限公司 | A kind of leonurine phenolic acid ion salt and the preparation method and application thereof |
| CN114796181A (en) * | 2021-01-27 | 2022-07-29 | 中国海洋大学 | Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nerve injury |
| CN114796183A (en) * | 2021-01-27 | 2022-07-29 | 中国海洋大学 | Application of leonurine in preparation of medicine for preventing or treating respiratory system diseases |
| CN114796182A (en) * | 2021-01-27 | 2022-07-29 | 中国海洋大学 | Application of leonurine in preparation of medicine for preventing and treating intermittent claudication |
-
2002
- 2002-09-02 CN CN 02138220 patent/CN1415603A/en active Pending
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015561A1 (en) * | 2007-08-02 | 2009-02-05 | Fudan University | The use of leonurine and compositions thereof |
| JP2010535159A (en) * | 2007-08-02 | 2010-11-18 | フダン ユニバーシティー | Use of Leonurine and compositions thereof |
| CN101357125B (en) * | 2007-08-02 | 2012-02-08 | 复旦大学 | Use of leonurine in preparing medicine for preventing and treating ischemic cardiomyopathy |
| CN103575816A (en) * | 2012-07-30 | 2014-02-12 | 天士力制药集团股份有限公司 | Method for detecting leonurine hydrochloride content in nephritis elimination tablet |
| CN103575816B (en) * | 2012-07-30 | 2015-09-09 | 天士力制药集团股份有限公司 | The detection method of leonurine hydrochloride content in the clear sheet of ephritis |
| CN110172032A (en) * | 2017-10-23 | 2019-08-27 | 珠海横琴新区中珠正泰医疗管理有限公司 | Leonurine crystal and application thereof |
| US11446270B2 (en) | 2017-10-23 | 2022-09-20 | Zhuhai Hengqin New District Zhongzhu Zhengtai Medical Management Co., Ltd. | Leonurine crystal and use thereof in preparation of insulin sensitizer, hypoglycemic drug and lipid-lowering drug |
| WO2019080671A1 (en) * | 2017-10-23 | 2019-05-02 | 珠海横琴新区中珠正泰医疗管理有限公司 | Leonurine crystal and use thereof in preparation of insulin sensitizer, hypoglycemic drug and lipid-lowering drug |
| CN110172032B (en) * | 2017-10-23 | 2023-06-30 | 珠海横琴新区中珠正泰医疗管理有限公司 | Leonurine crystal and application thereof |
| CN108129355A (en) * | 2018-01-18 | 2018-06-08 | 旌德新星生物科技有限公司 | A kind of hydrochloric acid leonurine alpha-crystal form and its preparation method and application |
| CN108129355B (en) * | 2018-01-18 | 2020-12-15 | 旌德新星生物科技有限公司 | Alpha crystal form of leonurine hydrochloride and preparation method and application thereof |
| CN110123664A (en) * | 2019-05-22 | 2019-08-16 | 中科萱嘉医养(珠海)健康科技有限公司 | A kind of supermolecule composition containing leonurine or inclusion compound and the preparation method and application thereof |
| CN110251501A (en) * | 2019-06-14 | 2019-09-20 | 中科萱嘉医养(珠海)健康科技有限公司 | A kind of leonurine phenolic acid ion salt and the preparation method and application thereof |
| CN110251501B (en) * | 2019-06-14 | 2022-04-15 | 中科萱嘉医养(珠海)健康科技有限公司 | Leonurine phenolic acid ion salt and preparation method and application thereof |
| CN114796183A (en) * | 2021-01-27 | 2022-07-29 | 中国海洋大学 | Application of leonurine in preparation of medicine for preventing or treating respiratory system diseases |
| CN114796182A (en) * | 2021-01-27 | 2022-07-29 | 中国海洋大学 | Application of leonurine in preparation of medicine for preventing and treating intermittent claudication |
| CN114796181A (en) * | 2021-01-27 | 2022-07-29 | 中国海洋大学 | Application of leonurine in preparation of medicine for preventing and treating non-vascular dementia or infectious central nerve injury |
| CN114796182B (en) * | 2021-01-27 | 2023-12-12 | 中国海洋大学 | Application of leonurine in preparing medicine for preventing and treating intermittent claudication |
| CN114796183B (en) * | 2021-01-27 | 2024-01-09 | 中国海洋大学 | Application of leonurine in preparing medicine for preventing or treating respiratory diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7381428B2 (en) | Stabilized lanthanum carbonate compositions | |
| ES2908719T3 (en) | Pharmaceutical compositions comprising iron oxy-hydroxide | |
| JPS60208979A (en) | Antiinflammatory novel compound obtained by combining beta-chiclodextrin | |
| KR101203186B1 (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof | |
| CN1820744A (en) | Oseltamivir phosphate granula and its preparing method | |
| CA3152326C (en) | Preparation of transmucosal psychoactive alkaloid composition | |
| CN1415603A (en) | Salt of leonurine and its preparation | |
| CN107913411B (en) | Ai Qubo Pa inclusion compound, its preparation and preparation method | |
| KR20040074052A (en) | Increased solubility flavanolignan preparations | |
| EP2389070B1 (en) | Disintegrable formulations of lanthanum carbonate | |
| WO2014076194A1 (en) | Effervescent tablet | |
| CN1915986A (en) | High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation | |
| CN115089618B (en) | A pharmaceutical composition for preventing and treating osteoporosis, and its preparation method | |
| CN1857295A (en) | Complex salt or composition medicine of breviscapine and basic amino acid for treating cardiac and cerebral vascular diseases | |
| CN1078468C (en) | Health-care products composition | |
| EP1233758A2 (en) | Sodium valproate granulate with reduced hygroscopicity | |
| KR100788454B1 (en) | Rapid-acting fomulation containing nateglinide as an active ingredient | |
| CN114832020B (en) | Pharmaceutical composition for preventing and treating child developmental disorder and preparation method thereof | |
| CN101125147A (en) | Glucosamine calcium medicine preparation, preparation method and application thereof | |
| WO2023172958A1 (en) | Stable formulations of talabostat | |
| WO2008125134A1 (en) | Process for the preparation of perindopril-tert-butylamine adsorbates | |
| JPH09268126A (en) | Preparation for treating digestive ulcer | |
| KR20190104974A (en) | Oral Administration Citrulline Malate Composition for supplying energy and preventing myasthenia | |
| Jagtap | Development and Characterization of Allicin Alginate Beads for Stomach-Specific Delivery | |
| JP2020533369A (en) | Method for preparing thymoquinone-containing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |